PR Newswire·Nov 12, 2026, 4:01 PM ET

Curis Provides Third Quarter 2026 Business Update

Curis, Inc. reported financial & operating results for the third quarter ended September 30, 2026, with a net loss of $8.1 million ($1.94 per share).
For the nine months ended September 30, 2026, the company reported a net loss of $40.9 million ($16.77 per share).
No revenue was reported for the quarter or year ended September 30, 2026, following the sale of Erivedge royalties in late 2025.
The company is enrolling patients in two ongoing studies: the TakeAim CLL study (emavusertib + zanubrutinib) & the TakeAim Lymphoma study (emavusertib + ibrutinib for PCNSL).
Initial data for the TakeAim CLL study involving 12 enrolled patients is expected in December 2026.
Updated data for the TakeAim Lymphoma study showed a 100% objective response rate (ORR) in BTKi-naïve patients & a 33% ORR in BTKi-experienced patients.
Regulatory guidance received in 2025 indicates the ongoing registrational study may support accelerated approval applications for R/R PCNSL.
Cash & cash equivalents totaled $5.0 million as of September 30, 2026, with total net proceeds of approximately $7.5 million from an October 2026 private placement extending the cash runway into Q1 2027.
Research & development expenses decreased to $5.6 million for the quarter, while general & administrative expenses decreased to $3.2 million due to lower employee-related costs.
Management will host a conference call on November 12, 2026, at 4:30 p.m. ET to discuss these results.